Atypical skin conditions of the neck and back as a dermal manifestation of anti-HMGCR antibody-positive myopathy
Open Access
- 11 May 2024
- journal article
- research article
- Published by Springer Nature in BMC Immunology
- Vol. 25 (1) , 1-10
Abstract
Background: Immune-mediated necrotizing myopathy (IMNM) is an idiopathic inflammatory myopathy (IIM). Though patients with IMNM were not considered to show skin rash, several reports have showed atypical skin conditions in patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody-positive IMNM (HMGCR-IMNM). The incidence and phenotype of skin conditions in patients with HMGCR-IMNM are not fully known. Results: Among the 100 IIM patients diagnosed from April 2015 through August 2022, 34 (34%) presented some form of skin condition, with 27 having typical skin rashes; this included 13 patients with dermatomyositis (DM), 8 with anti-synthetase syndrome (ASS), and 6 with IMNM. Meanwhile, 8 of 19 patients with HMGCR-IMNM (42%) presented atypical skin lesions, but no patients with other IIMs did (p < 0.001). Skin eruption with ash-like scales was observed in four HMGCR-IMNM patients, and non-scaly red patches and lumps in the other four patients; accordingly, their skin manifestations were considered as other dermal diseases except for IIM. However, skin and muscle biopsies revealed the atypical skin conditions of patients with HMGCR-IMNM to have the same pathological background, formed by Bcl-2-positive lymphocyte infiltrations. Conclusions: HMGCR-IMNM patients frequently have atypical skin conditions of the neck and back. Skin biopsy specimens from these lesions showed the same Bcl-2-positive lymphocytic infiltrations as muscle biopsy specimens regardless of the different gross dermal findings. Thus, such atypical skin conditions may be suggestive for HMGCR-IMNM.Keywords
Funding Information
- Daiichi Sankyo Foundation of Life Science
- Kato Memorial Trust for Nanbyo Research
- Kurozumi Medical Foundation
- Okinaka Memorial Institute for Medical Research
- Takeda Science Foundation
- Tsuchiya Foundation
This publication has 32 references indexed in Scilit:
- Anti-signal recognition particle autoantibodies: marker of a necrotising myopathyAnnals of the Rheumatic Diseases, 2006
- Statin therapy and autoimmune disease: from protein prenylation to immunomodulationNature Reviews Immunology, 2006
- Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery diseaseJACC, 2003
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Myopathy with antibodies to the signal recognition particle: clinical and pathological featuresJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Statins as a newly recognized type of immunomodulatorNature Medicine, 2000
- Inclusion body myositis and myopathiesAnnals of Neurology, 1995
- Antibody to signal recognition particle in polymyositisArthritis & Rheumatism, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Polymyositis and DermatomyositisNew England Journal of Medicine, 1975